The 3yr. results from the P-III (CheckMate -9LA) trial evaluating Opdivo + Yervoy & CT vs CT alone & 5 yr. results from part 1 of the P-III (CheckMate -227) trial of Opdivo + Yervoy vs CT for mNSCLC
In both trials, the results showed OS benefits at a minimum follow-up of 3 or 5yrs., OS rate (25% & 24% vs 15% & 14%) in patients with tumor PD-L1 expression <1% & ≥1%; patients were alive (27% & 19% vs 19% & 7%). In (CheckMate -9LA) trial, OS benefit & durable clinical benefit were observed in an exploratory analysis & OS rate (24% vs 11%) in sq. histology
In PD-L1 ≥1% & <1% in (CheckMate -227) trial, patients responded (28% & 21% vs 3% & 0%); alive (66% & 64%). The safety profile was consistent with prior reported data with no new safety signals
Ref: BMS | Image: BMS
